Share this article on:

Is Peroxisome Proliferator- activated Receptor (PPAR) Genotype A Useful Predictor For Body-weight Reduction?: 1505Board #268 May 30 9:30 AM - 11:00 AM

Matsuo, Tomoaki; Nakata, Yoshio; Okura, Tomohiro; Hotta, Kikuko; Tanaka, Kiyoji FACSM

Medicine & Science in Sports & Exercise: May 2007 - Volume 39 - Issue 5 - p S228
doi: 10.1249/01.mss.0000273864.17181.8e
A-37 Free Communication/Poster -Weight Loss: MAY 30, 2007 7:30 AM - 12:30 PM ROOM: Hall E

1University of Tsukuba, Tsukuba, Japan.

2Institure of Physical and Chemical Research, Yokohama, Japan.


An individual's genetic information, which is available as an additional determinant for body-weight reduction, may be able to modify the weight reduction program. Single-nucleotide polymorphism (SNP) is one of the important factors to explain various differences in human individuals. Peroxisome proliferator activated receptor (PPAR) plays a key role in the regulation of lipid and glucose metabolisms and body fat distribution. Several researchers suggest a significant relationship between the PPAR genotype and body-weight change. It is unclear, however, whether PPAR genotype is a useful as decisive factor in weight-reduction.

PURPOSE: To investigate the relationship between the PPAR genotype and body-weight change in response to a 14-week intervention, and to quantify the contribution of PPAR genotype as additional information for weight reduction program.

METHODS: In total, 282 middle-aged Japanese women (age, 48.9±9.1 years; body mass index, 27.1±3.1 kg/m2) participated in a 14-week diet and exercise intervention program as subjects. Genetic information about PPAR was analyzed (7 SNPs of peroxisome proliferator activated receptor γ; PPARG, 3 SNPs of peroxisome proliferator activated receptor α; PPARA and 10 SNPs of peroxisome proliferator activated receptor γ coactivator 1; PPARGC1).

RESULTS: Body-weight decreased significantly (−7.9±3.0 kg, −11.9±4.0%) following the intervention. An analysis of covariance (ANCOVA) was used to test for differences in the amount of body-weight reduction among each of the genotypes using baseline body mass index as a covariate. As a result, only one SNP (PPARG) had a strong relationship (p = 0.0009) with the amount of body-weight reduction. In a multiple regression model, baseline body mass index accounted for 12% of the total variance in body-weight change. The percentage increased to 17% when PPAR genotype was included the model.

CONCLUSIONS: These data suggest that PPAR genotype influences the change in body-weight in response to a 14-week weight reduction intervention among obese middle-aged Japanese women. The PPAR genotype accounted for additional 5% of the total body-weight reduction variance.

© 2007 American College of Sports Medicine